2.655

1.00% -0.015

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $2.655, with a volume of 341.70K. It is down -1.00% in the last 24 hours and down -4.57% over the past month. AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Previous Close:

$2.67

Open:

$2.66

24h Volume:

341.70K

Relative Volume:

0.16

Market Cap:

$788.63M

Revenue:

$38.03M

Net Income/Loss:

$-146.40M

P/E Ratio:

-5.90

EPS:

-0.45

Net Cash Flow:

$-121.38M

1W Performance:

-4.22%

1M Performance:

-4.57%

6M Performance:

-31.34%

1Y Performance:

-39.09%

1-Day Range:

$2.61

$2.7075

1-Week Range:

$2.57

$2.76

52-Week Range:

$2.335

$6.055

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

(604) 559-9005

Address

2215 YUKON STREET, VANCOUVER

Employee

586

Twitter

Next Earnings Date

2024-11-18

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL	2.655	788.63M	38.03M	-146.40M	-121.38M	-0.45
VRTX	447.62	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.31	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.39	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.88	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.29	24.49B	3.30B	-501.07M	1.03B	11.54

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

Nov 20, 2024

ABCL (AbCellera Biologics) Goodwill-to-Asset : 0.03 (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

ABCL (AbCellera Biologics) EBIT per Share : $-1.00 (TTM As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 19, 2024

GSA Capital Partners LLP Boosts Stock Position in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat

Nov 19, 2024

Nov 13, 2024

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Baillie Gifford & Co. - MarketBeat

Nov 13, 2024

Nov 11, 2024

AbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading VolumeShould You Buy? - MarketBeat

Nov 11, 2024

Nov 08, 2024

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 - Business Wire

Nov 07, 2024

AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St

Nov 07, 2024

Leerink Partnrs Has Pessimistic View of ABCL FY2024 Earnings - MarketBeat

Nov 07, 2024

AbCellera Unveils Breakthrough T-Cell Platform Data, Shows Promise in Cancer Treatment | ABCL Stock News - StockTitan

Nov 07, 2024

Nov 06, 2024

AbCellera Biologics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 06, 2024

Nov 05, 2024

AbCellera Biologics (NASDAQ:ABCL) Given "Hold" Rating at Benchmark - MarketBeat

Nov 05, 2024

AbCellera Biologics (NASDAQ:ABCL) Given "Buy" Rating at Stifel Nicolaus - MarketBeat

Nov 05, 2024

AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down After Earnings Miss - MarketBeat

Nov 05, 2024

AbCellera Biologics (NASDAQ:ABCL) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat

Nov 05, 2024

AbCellera stock price target cut, keeps Outperform on strategic pivot By Investing.com - Investing.com UK

Nov 05, 2024

AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 05, 2024